行情

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

实时行情|Nasdaq Last Sale

0.6493
-0.0254
-3.76%
已收盘, 16:00 04/02 EDT
开盘
0.6400
昨收
0.6747
最高
0.7225
最低
0.6153
成交量
8.98万
成交额
--
52周最高
9.45
52周最低
0.6153
市值
992.47万
市盈率(TTM)
-0.5580
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PDSB价格均价为7.73,最高价位10.00,最低价为5.45。

EPS

PDSB 新闻

更多
  • 瑞幸咖啡盘前反弹 现涨2.8%
  • 新浪财经 · 37分钟前
  • 神州租车疑似回应暴跌:一路上有风雨 但我们保持前行
  • 新浪科技 · 43分钟前
  • 特朗普推动减产之际 OPEC+将于下周一举行网络会议
  • 新浪财经 · 54分钟前
  • 22亿财务造假“连环炸”!央视记者探访瑞幸北京总部
  • 新浪科技综合 · 57分钟前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

PDSB 简况

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
展开

微牛提供PDS Biotechnology Corp(NASDAQ-PDSB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PDSB股票新闻,以帮助您做出投资决策。